ReviewMolecular medicine reports2026
Oncogene c‑Myc: From molecular mechanism to targeted therapy (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
c‑Myc, a member of the MYC family, is an extensively studied proto‑oncogenic transcription factor that plays crucial roles in various biological processes of tumor cells, including proliferation, cell cycle regulation, DNA damage repair, metabolic reprogramming, differentiation and genomic maintenance. Furthermore, in cancer therapeutics, c‑Myc may serve as a key factor influencing targeted drug efficacy and tumor drug resistance. This review comprehensively summarizes the structural characteristics of c‑Myc and its roles and key molecular mechanisms across various malignancies, as well as current strategies for c‑Myc‑targeted therapies and related clinical trials. Additionally, the existing challenges in c‑Myc research are discussed and future research directions are being outlined. The synthesis aims to provide novel insights for fundamental research, offer new perspectives for precision cancer therapy in clinical practice and ultimately bring renewed hope for cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.